Synthesis and pharmacological evaluation of CGP 57813 and CGP 61755, HIV-1 protease inhibitors from the Phe-c-Phe peptidomimetic class

Antiviral Chemistry and Chemotherapy

Volumn 7, Issue 6, 1996, Pages 294-299

  Cozens, R M ^a   Bold, G ^a   Capraro, H G ^a   Fassler A ^a   Mestan, J ^a   Lang, M ^a   Poncioni, B ^a   Stover, D ^a   Rosel J L ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

CGP 57813; HIV; HIV protease inhibitors CGP 61755; inhibitors

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASPARTIC PROTEINASE; CGP 53437; CGP 57813; DIMETHYL SULFOXIDE; INDINAVIR; LASINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; SESAME SEED OIL; UNCLASSIFIED DRUG; VIRUS ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL LINE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029801256     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029600700602     Document Type: Article

References (16)

1. Alteri, E., Bold, G., Cozens, R., Fässler, A., Klimkait, T., Lang, M., Lazdins, J.K., Poncioni, B., Rösel, J.L., Schneider, P., Walker, M., and Woods-Cook, K. (1993) CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agent Chemother 37: 2087-2092.
2. Capraro, H-G., Bold, G., Fässler, A., Cozens, R., Klimkait, T., Lazains, J., Mestan, J., Poncioni, B., Rösel J.L., Stover, D., and Lang, M. (1996) Synthesis of potent and orally active HIV-protease inhibitors. Arch Pharm Med Chem, 329: 273-278.
3. De Camp, A.E., Kawaguchi, A.T., Volante, R.P., and Shinkai, I. (1991) Stereocontrolled addition of propionate homoenolate equivalents to chiral alfa-amino aldehyds. Tetrahedron Lett 32: 1867-1870.
4. De Clercq, E. (1995) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 38: 2492-2517.
5. Gallo, R.C., Salahuddin, S.Z., Popovic, M., Shearer, G.M., Kaplan, M., Haynes, B.F., Palker, T.J., Redfield, R., Oleska, J., Safai, B., White, G., Foster, P., and Markham, P.D. (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500-503.
6. Ghosh, A.K., Sean, P., McKee, S.P., and Thompson, W.J. (1991) An efficient synthesis of hydroxyethylene dipeptide isosteres: the core unit of potent HIV-1 protease inhibitors. J Org Chem 56: 6500-6503.
7. Jupp, R.A., Dunn, B.M., Jacobs, J.W., Vlasuk, G., Arcuri, K.E., Veber, D.F.S., Perow, D.S., Payne, L.S., Boger, J., DeLazlo, S., Chakrabarty, P.K., TenBroeke, J., Hangauer, D.G., Ondeyka, D., Greenlee, W.J., and Kay, J. (1990) The selectivity of statine-based inhibitors against various human aspartic proteases. Biochem J265: 871-878.
8. Leroux, J.C., Cozens, R., Roesel, J.L., Galli, B., Kugel, F., Doelker, E., and Gurny, R. (1995) Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci 84: 1387-1391.
9. Leroux, J.C., Cozens, R., Roesel, J.L., Galli, B., Doelker, E., and Gumy, R. (1996) pH-Sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors to dogs. Pharm Res 13: 485-487.
10. Matayoshi, E.D., Wand, G.T., Krafft, G.A., and Erickson, J. (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247: 954-958.
11. Roberts, N.A., Martin, J.A., Kinchington, D., Broadhurst, A.V., Craig, J.C., Duncan, I.E., Galpin, S.A., Handa, B., Kay, J., Krohn, A., Lambert, R.W., Merrett, J.H., Mills, J.S., Parkes, K-E.B., Redshaw, S., Ritchie, A.J., Taylor, D.L., Thomas, G.J., Machin, P.J. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248: 358-361.
12. Scudiero, D.A., Shoemaker, R.H., Paull, K.D., Monks, A., Tierney, S., Nofziger, T.H., Currens, M.J., Seniff, D., and Boyd, M. (1988) Evaluation of a soluble Tetrazolium/Formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4833.
13. Vacca, J.P., Dorsey, B.D., Schleif, W.A., Levin, R.B., McDaniel, S.L., Darke, P.L., Zugay, J., Quintero, U.C., Blahy, O.M., Roth, E., Sardana, V.V., Schlabach, A.J., Graham, P.I., Condra, J.H., Gotlib, L., Holloway, M.K., Lin, J., Chen, J.-W., Vastag, K., Ostovic, D., Anderson, P.S., Emini, E.A., Huff, J.R. (1994) L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 91: 4096-4100.
14. West, M.L., and Fairlie, D.P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. Trends in Pharmacological Science 16: 67-75.
15. Willey, R., Smith, D., Lasky, L., Theodore, T., Earl, P., Moss, B., Capon, D., and Martin, M. (1988) In vitro mutagenesis identifies a region within the envelope gene of human immunodeficiency virus that is critical for infectivity. J Virol 62: 139-147.
16. Wood, J.M., Criscione, L., deGasparo, M., Bühlmayer, P., Rüeger, H., Stanton, J., Jupp, R.A., and Kay, J. (1989) CGP 38560: orally active low molecular-weight renin inhibitor with high potency and specificity. J Card Pharm 14: 221-226.